Dolutegravir Based Regimens

  • Congress Data

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

  • Clinical Trials Data

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

  • Dosing

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director

  • Pharmacokinetics

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director

  • Safety

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

  • Virology/Resistance

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research

  • Real World Evidence

    Dovato Real World Evidence Video

    Dr. Benjamin Young, Head of Global Medical Directors

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir